Skip to content
Screener

Arrowhead Research ARWR Cash & Equivalents

Cash & Equivalents at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$350.07M+17.7%
ALN
Alnylam PharmaceuticalsALNY
$1.71B+53.2%
Assembly Biosciences logo
Assembly BiosciencesASMB
$31.12M+32.9%
Arbutus Biopharma Corporation logo
Arbutus Biopharma CorporationABUS
$23.71M-36.1%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$125M-29.0%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$288.29M-45.4%

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$12.28B+445%
Enterprise value$12.2B+446%
P/S19.7×+15.8×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The source filing: Arrowhead Research’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q1 2026
Accession
0000879407-26-000047
Line itemSix Months Ended March 31, 2026Six Months Ended March 31, 2025
Effect of exchange rate on cash, cash equivalents and restricted cash1,103(470)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH:
BEGINNING OF PERIOD226,548102,685
END OF PERIOD$188,517$185,709
Supplemental disclosure of cash flows:
Interest paid$(19)
Income taxes paid$(21,565)$(81)
Supplemental disclosure of non-cash investing activities:

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Arrowhead Research's cash & equivalents?
Arrowhead Research (ARWR) reported cash & equivalents of $188.52M in Q1 2026.
How has Arrowhead Research's cash & equivalents changed year-over-year?
Arrowhead Research's cash & equivalents increased by 1.5% year-over-year, from $185.71M to $188.52M.
What is the long-term trend for Arrowhead Research's cash & equivalents?
Over 4 years (2021 to 2025), Arrowhead Research's cash & equivalents has grown at a 5.3% compound annual growth rate (CAGR), from $184.43M to $226.55M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about Arrowhead Research's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude